Literature DB >> 18472240

Assessment of breast cancer response to neoadjuvant chemotherapy: is volumetric MRI a reliable tool?

Michele Lorenzon1, Chiara Zuiani, Viviana Londero, Anna Linda, Alessandro Furlan, Massimo Bazzocchi.   

Abstract

The purpose of this study was to evaluate the reliability of volumetric magnetic resonance imaging (MRI) in breast cancer size assessment before, during and after neoadjuvant chemotherapy (NAC). Volumetric MRI measures performed on 15 patients with breast cancer were compared with volumes reckoned upon mean lesional diameters, using the same MRI data. Concordance correlation coefficient (CCC), Bland & Altman plots, RECIST evaluation and Cohen's Kappa were assessed, to evaluate the agreement between the two methods. CCC was computed before (0.9357), during (0.8053) and after (0.7499) NAC, in all examinations pooled together (0.8617), and on final tumor volume as a percentage of baseline volume (0.9224). In 2/15 (13.3%) cases RECIST assessment was different. Cohen's Kappa was 0.787 (CI(95%)=0.513-1.062). In summary, volumetric MRI is a reliable tool to assess breast cancer size before, during and after NAC. Further investigations are needed to understand whether improvements in surgical planning are feasible.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18472240     DOI: 10.1016/j.ejrad.2008.03.021

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  10 in total

1.  Comparison between different imaging techniques in the evaluation of malignant breast lesions: can 3D ultrasound be useful?

Authors:  Paola Clauser; Viviana Londero; Giuseppe Como; Rossano Girometti; Massimo Bazzocchi; Chiara Zuiani
Journal:  Radiol Med       Date:  2013-12-03       Impact factor: 3.469

Review 2.  MRI in breast cancer therapy monitoring.

Authors:  Rebekah McLaughlin; Nola Hylton
Journal:  NMR Biomed       Date:  2011-06-21       Impact factor: 4.044

3.  Comparison of the diagnostic performance of response evaluation criteria in solid tumor 1.0 with response evaluation criteria in solid tumor 1.1 on MRI in advanced breast cancer response evaluation to neoadjuvant chemotherapy.

Authors:  Su Kyung Jeh; Sung Hun Kim; Bong Joo Kang
Journal:  Korean J Radiol       Date:  2012-12-28       Impact factor: 3.500

Review 4.  Invited review--neuroimaging response assessment criteria for brain tumors in veterinary patients.

Authors:  John H Rossmeisl; Paulo A Garcia; Gregory B Daniel; John Daniel Bourland; Waldemar Debinski; Nikolaos Dervisis; Shawna Klahn
Journal:  Vet Radiol Ultrasound       Date:  2013-11-13       Impact factor: 1.363

5.  Clinical validation of semi-automated software for volumetric and dynamic contrast enhancement analysis of soft tissue venous malformations on magnetic resonance imaging examination.

Authors:  Véronique Caty; Claude Kauffmann; Josée Dubois; Asmaa Mansour; Marie-France Giroux; Vincent Oliva; Nicolas Piché; Eric Therasse; Gilles Soulez
Journal:  Eur Radiol       Date:  2013-11-30       Impact factor: 5.315

6.  A novel method for volumetric MRI response assessment of enhancing brain tumors.

Authors:  Charles W Kanaly; Dale Ding; Ankit I Mehta; Anthony F Waller; Ian Crocker; Annick Desjardins; David A Reardon; Allan H Friedman; Darell D Bigner; John H Sampson
Journal:  PLoS One       Date:  2011-01-26       Impact factor: 3.240

Review 7.  Monitoring radiographic brain tumor progression.

Authors:  Ankit I Mehta; Charles W Kanaly; Allan H Friedman; Darell D Bigner; John H Sampson
Journal:  Toxins (Basel)       Date:  2011-03-15       Impact factor: 4.546

8.  Preoperative MRI features predict failed breast-conserving surgery: construction of a predictive model.

Authors:  Yu-Hong Qu; Ying-Jian He; Xiao-Ting Li; Zhao-Qing Fan; Rui-Jia Sun; Xing Wang; Tao Ouyang; Ying-Shi Sun
Journal:  Transl Cancer Res       Date:  2022-04       Impact factor: 1.241

9.  DCE-MRI Texture Features for Early Prediction of Breast Cancer Therapy Response.

Authors:  Guillaume Thibault; Alina Tudorica; Aneela Afzal; Stephen Y-C Chui; Arpana Naik; Megan L Troxell; Kathleen A Kemmer; Karen Y Oh; Nicole Roy; Neda Jafarian; Megan L Holtorf; Wei Huang; Xubo Song
Journal:  Tomography       Date:  2017-03

10.  Clinically meaningful tumor reduction rates vary by prechemotherapy MRI phenotype and tumor subtype in the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).

Authors:  Rita A Mukhtar; Christina Yau; Mark Rosen; Vickram J Tandon; Nola Hylton; Laura J Esserman
Journal:  Ann Surg Oncol       Date:  2013-06-19       Impact factor: 5.344

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.